Literature DB >> 22552455

Previous use of quinolones: a surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients?

Caroline Deutschendorf1, Luciano Z Goldani, Rodrigo Pires dos Santos.   

Abstract

OBJECTIVES: Drug resistant Mycobacterium tuberculosis causes much higher rates of treatment toxicity, failure or relapse, and mortality. We determined the drug resistant profile of Mycobacterium tuberculosis strains isolated from a population of HIV-infected patients in southern Brazil and studied the potential factors associated with resistance.
METHODS: We conducted a retrospective cohort study to determine the resistance profile of Mycobacterium tuberculosis isolated from HIV-infected patients and factors that could be associated with resistance from 2000 to 2005.
RESULTS: 236 patients were included in the study. Resistance to at least one drug was observed in 32 (14.6%) isolates, and multi-drug resistance was observed in 4 (1.82%) isolates. On multivariate analysis, previous use of tuberculostatics and quinolones were related to any first-line drug resistance.
CONCLUSIONS: In our study, previous quinolone use was significantly associated to first-line anti-TB drugs resistance. Multi-drug-resistant tuberculosis (MDR-TB) is a major problem worldwide, and we believe quinolones should be used with caution in settings where TB is endemic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552455     DOI: 10.1016/s1413-8670(12)70295-7

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  2 in total

Review 1.  Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis.

Authors:  Cajetan C Onyedum; Isaac Alobu; Kingsley Nnanna Ukwaja
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

2.  A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection?

Authors:  Asres Berhan; Yifru Berhan; Desalegn Yizengaw
Journal:  Ethiop J Health Sci       Date:  2013-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.